FMP

FMP

Enter

LYRA - Lyra Therapeutics, I...

Financial Summary of Lyra Therapeutics, Inc.(LYRA), Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and comme

photo-url-https://financialmodelingprep.com/image-stock/LYRA.png

Lyra Therapeutics, Inc.

LYRA

NASDAQ

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

5.23 USD

0.02 (0.382%)

About

ceo

Dr. Maria Palasis Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://lyratherapeutics.com

exchange

NASDAQ

Description

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its ...

CIK

0001327273

ISIN

US55234L1052

CUSIP

55234L105

Address

480 Arsenal Way

Phone

617 393 4600

Country

US

Employee

88

IPO Date

May 1, 2020

Summary

CIK

0001327273

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

55234L105

ISIN

US55234L1052

Country

US

Price

5.23

Beta

0.23

Volume Avg.

345.97k

Market Cap

312.46M

Shares

-

52-Week

2.01-6.79

DCF

-1.56

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-4.15

P/B

-

Website

https://lyratherapeutics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest LYRA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep